APP and Alzheimer disease: Posiphen, an inhibitor of the transcription of APP mRNA through the targeting of the iron-response element (IRE), has been demonstrated to reduce APP mRNA at the transcriptional level, having completed phase III clinical trials with mild to moderate AD [13].